Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer

被引：1

作者：

Volmer, Lea Louise ^{[1
]}

Dannehl, Dominik ^{[1
]}

Matovina, Sabine ^{[1
]}

Taran, Florin-Andrei ^{[2
]}

Walter, Christina Barbara ^{[1
]}

Wallwiener, Markus ^{[3
]}

Brucker, Sara Yvonne ^{[1
]}

Hartkopf, Andreas Daniel ^{[1
]}

Engler, Tobias ^{[1
]}

机构：

[1] Tubingen Univ, Dept Womens Hlth, D-72076 Tubingen, Germany

[2] Freiburg Univ, Dept Gynecol & Obstet, D-79085 Freiburg, Germany

[3] Univ Med Ctr Halle, Dept Gynecol & Obstet, D-06120 Halle, Saale, Germany

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 11期

关键词：

disseminated tumor cells; minimal residual disease; breast cancer; targeted therapy; BONE-MARROW; THERAPY; METASTASIS;

D O I：

10.3390/ijms25115910

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Breast cancer remains a leading cause of cancer mortality in women globally. Despite advancements in systemic therapy, the risk of distant recurrence persists even after such treatment and may be linked to disseminated tumor cells (DTCs). Variability in molecular characteristics between primary tumors (PTs) and distant metastases underscores the need to comprehensively understand metastatic pathways. This retrospective study investigated discrepancies between HER2 expression in PTs and DTCs and their implications for survival outcomes in 201 early breast cancer (EBC) patients. We found a significant association between HER2 expression in PTs and DTCs when classifying tumors as HER2-high/low/negative. Patients whose HER2 status was discordant between PTs and DTCs exhibited worse distant disease-free survival than those with concordant status. Multivariate analysis confirmed the HER2 status of DTCs as an independent prognostic factor for distant DFS. These findings emphasize the importance of assessing HER2 expression in DTCs and its potential implications for tailored therapy strategies in EBC. Furthermore, prospective trials are needed to validate these findings and explore targeted therapies based on the molecular characteristics of DTCs.

引用

页数：12

共 45 条

[1] Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer [J].

Almstedt, Katrin ;

Krauthauser, Lisa ;

Kappenberg, Franziska ;

Wagner, Daniel-Christoph ;

Heimes, Anne-Sophie ;

Battista, Marco J. J. ;

Anic, Katharina ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Schwab, Roxana ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. G. ;

Roth, Wilfried ;

Hasenburg, Annette ;

Stewen, Kathrin ;

Schmidt, Marcus .

CANCERS, 2023, 15 (05)

[2]

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Interdisziplinare S3-Leitlinie fur die Fruherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms

[3] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[4]

Becker S, 2005, ANTICANCER RES, V25, P2171

[5]

Braun S, 2001, CANCER RES, V61, P1890

[6] A pooled analysis of bone marrow micrometastasis in breast cancer [J].

Braun, S ;

Vogl, FD ;

Naume, B ;

Janni, W ;

Osborne, MP ;

Coombes, RC ;

Schlimok, G ;

Diel, IJ ;

Gerber, B ;

Gebauer, G ;

Pierga, JY ;

Marth, C ;

Oruzio, D ;

Wiedswang, G ;

Solomayer, EF ;

Kundt, G ;

Strobl, B ;

Fehm, T ;

Wong, GYC ;

Bliss, J ;

Vincent-Salomon, A ;

Pantel, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802

[7] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases [J].

Cai, Mengyuan ;

Li, Ming ;

Lv, Hong ;

Zhou, Shuling ;

Xu, Xiaoli ;

Shui, Ruohong ;

Yang, Wentao .

BMC CANCER, 2023, 23 (01)

[8] Breast tumor heterogeneity [J].

Campbell, Lauren L. ;

Polyak, Kornelia .

CELL CYCLE, 2007, 6 (19) :2332-2338

[9]

clinicaltrials.gov, HER2-Positive Early Breast Cancer

[10] Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 [J].

Curigliano, G. ;

Burstein, H. J. ;

Gnant, M. ;

Loibl, S. ;

Cameron, D. ;

Regan, M. M. ;

Denkert, C. ;

Poortmans, P. ;

Weber, W. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2023, 34 (11) :970-986

← 1 2 3 4 5 →